Stocks and Investing Stocks and Investing
Mon, January 27, 2025
[ Last Monday ] - WOPRAI
Short squeeze is starting in shares of SWTX at $3 .. 7, after crossing above the $37.728 Trigger Price
[ Last Monday ] - WOPRAI
Short squeeze is starting in shares of STKL at $7 .. 59, after crossing above the $7.494 Trigger Price
[ Last Monday ] - WOPRAI
Short squeeze is starting in shares of NATR at $1 .. 9, after crossing above the $14.886 Trigger Price
[ Last Monday ] - WOPRAI
Short squeeze is starting in shares of LANC at $1 .. , after crossing above the $174.121 Trigger Price
[ Last Monday ] - WOPRAI
Short squeeze is starting in shares of KZR at $6. .. 92, after crossing above the $6.561 Trigger Price
[ Last Monday ] - WOPRAI
Short squeeze is starting in shares of HTH at $29 .. 5, after crossing above the $29.177 Trigger Price
[ Last Monday ] - WOPRAI
Short squeeze is starting in shares of DHC at $2.32, after crossing above the $2.29 Trigger Price
[ Last Monday ] - WOPRAI
Short squeeze is starting in shares of DFH at $25 .. 5, after crossing above the $25.219 Trigger Price
[ Last Monday ] - WOPRAI
Short squeeze is starting in shares of CPT at $11 .. , after crossing above the $112.381 Trigger Price
[ Last Monday ] - WOPRAI
Short squeeze is starting in shares of BXP at $75 .. 67, after crossing above the $75.63 Trigger Price
[ Last Monday ] - WOPRAI
Short squeeze is starting in shares of ANGO at $1 .. 3, after crossing above the $12.612 Trigger Price
[ Last Monday ] - FXStreet
Tech turmoil: DeepSeek disruption sends markets into a tailspin
[ Last Monday ] - WOPRAI
Short squeeze is starting in shares of WMK at $64 .. 4, after crossing above the $64.503 Trigger Price
[ Last Monday ] - WOPRAI
Short squeeze is starting in shares of MMS at $76 .. 5, after crossing above the $76.394 Trigger Price
[ Last Monday ] - WOPRAI
Short squeeze is starting in shares of FRST at $1 .. 8, after crossing above the $11.507 Trigger Price
[ Last Monday ] - WOPRAI
Short squeeze is starting in shares of CASS at $4 .. 5, after crossing above the $41.297 Trigger Price
[ Last Monday ] - WOPRAI
Short squeeze is starting in shares of BUSE at $2 .. 2, after crossing above the $22.947 Trigger Price
[ Last Monday ] - WOPRAI
Short squeeze is starting in shares of BDX at $24 .. , after crossing above the $245.919 Trigger Price
[ Last Monday ] - MSN
What to expect from stock markets ahead of Budget 2025? Kranthi Bathini's take
[ Last Monday ] - Indiatimes
Capital Numbers shares list with 4% premium on BSE SME platform
[ Last Monday ] - WOPRAI
Short squeeze is starting in shares of SLAM at $1 .. 4, after crossing above the $10.197 Trigger Price
[ Last Monday ] - WOPRAI
Short squeeze is starting in shares of RNECF at $ .. 4, after crossing above the $13.482 Trigger Price
[ Last Monday ] - WOPRAI
Short squeeze is starting in shares of PCYO at $1 .. 1, after crossing above the $11.161 Trigger Price
[ Last Monday ] - WOPRAI
Short squeeze is starting in shares of OCEL at $2 .. 69, after crossing above the $0.023 Trigger Price
[ Last Monday ] - WOPRAI
Short squeeze is starting in shares of MGLD at $1.6, after crossing above the $1.551 Trigger Price
[ Last Monday ] - WOPRAI
Short squeeze is starting in shares of EXK at $3. .. 75, after crossing above the $3.603 Trigger Price
[ Last Monday ] - WOPRAI
Short squeeze is starting in shares of BKD at $4.945, after crossing above the $4.93 Trigger Price
[ Last Monday ] - WOPRAI
Short squeeze is starting in shares of ATEC at $1 .. 5, after crossing above the $11.099 Trigger Price
[ Last Monday ] - MSN
If You'd Invested $100 in PayPal Stock 10 Years Ago, Here's What It Would Be Worth Today
[ Last Monday ] - MSN
Goldman Sachs raises AbbVie stock price target to $208

Goldman Sachs raises AbbVie stock price target to $208


Published on 2025-01-27 08:01:31 - MSN
  Print publication without navigation

  • Goldman Sachs updated its financial model for AbbVie (NYSE:ABBV), leading to an increase in the price target for the pharmaceutical company's shares to $208.00, up from the previous target of $205.00.

Goldman Sachs has increased its price target for AbbVie Inc. to $208 from $173, maintaining a "buy" rating on the stock. This adjustment reflects optimism about AbbVie's future performance, particularly due to the potential of its new drug, Skyrizi, which is expected to drive significant revenue growth. The stock has already seen a 10% increase year-to-date, and with the new price target, Goldman Sachs analysts suggest that AbbVie could see further gains, supported by its robust pipeline and strategic market positioning.

Read the Full MSN Article at:
[ https://www.msn.com/en-us/money/top-stocks/goldman-sachs-raises-abbvie-stock-price-target-to-208/ar-AA1xWese ]
Contributing Sources